The total return over the past 12 months is +45.87% vs. +19.37% for the S&P 500. So far it's up +5.38% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | +45.14% | (0.82%) | +3.90% | +7.27% | +17.49% | +21.68% |
| Total Return CAGR | +45.87% | (0.52%) | +4.09% | +7.37% | +17.56% | +21.74% |
| Revenue CAGR | +9.29% | +7.03% | +4.64% | +12.82% | +26.45% | +30.91% |
| Net Income CAGR | (2.91%) | +0.23% | +5.10% | +19.53% | N/A | +24.11% |
| EPS CAGR | +0.31% | +2.06% | +5.70% | +21.44% | N/A | +21.27% |
| Free Cash Flow CAGR | (8.39%) | (5.34%) | +15.77% | +12.84% | +61.28% | +25.49% |
| Operating Cash Flow CAGR | (6.34%) | (2.13%) | +14.36% | +10.62% | +31.35% | +25.64% |
| Dividends CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
Regeneron Pharmaceuticals, Inc. (REGN)
| Year | Start price | End price | REGN Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | $771.87 | $810.31 | +5.38% | +12.92% | (7.54%) |
| 2025 | $712.33 | $771.87 | +8.95% | +17.72% | (8.77%) |
| 2024 | $878.29 | $712.33 | (18.90%) | +24.89% | (43.79%) |
| 2023 | $721.49 | $878.29 | +21.73% | +26.19% | (4.46%) |
| 2022 | $631.52 | $721.49 | +14.25% | (18.17%) | +32.42% |
| 2021 | $483.11 | $631.52 | +30.72% | +28.74% | +1.98% |
| 2020 | $375.48 | $483.11 | +28.66% | +18.37% | +10.29% |
| 2019 | $373.50 | $375.48 | +0.53% | +31.22% | (30.69%) |
| 2018 | $375.96 | $373.50 | (0.65%) | (4.56%) | +3.91% |
| 2017 | $367.09 | $375.96 | +2.42% | +21.70% | (19.28%) |
Start and end prices are split-adjusted closing prices. Total return includes reinvested dividends, so it can differ from the price change.
